Actualités et communiqués de presse Biohaven 2026 | BHVN | ISIN VGG1110E1079

Actualités Eulerpool Biohaven

Actualités de l'action Biohaven

Biohaven est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Biohaven.

5 novembre·
Benzinga
Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EU
18 septembre·
Yahoo
Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.
18 septembre·
Benzinga
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
18 septembre·
Benzinga
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
10 septembre·
SeekingAlpha
Biohaven: The Hold Isn't The Problem (Rating Downgrade)
10 septembre·
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
10 septembre·
ChartMill
These stocks that are showing activity before the opening bell on Thursday.
10 septembre·
Benzinga
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
10 septembre·
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 septembre·
Benzinga
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
21 janvier·
Fintel
RBC Capital Upgrades Biohaven (BHVN)
12 janvier·
SeekingAlpha
Biohaven Ltd. (BHVN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
12 janvier·
Benzinga
Biohaven Reports Early Clinical Data Across IgA Nephropathy, Graves' Disease, Epilepsy, Obesity And Oncology Programs; Demonstrates Rapid Protein Degradation, Robust Clinical Responses And Well-Tolerated Safety Profiles; Multiple Pivotal Trials Planned For 2026
26 décembre·
SeekingAlpha
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
26 décembre·
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
26 décembre·
Benzinga
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday
25 décembre·
Benzinga
What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?
24 décembre·
Yahoo
Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know
24 décembre·
Benzinga
Biohaven To Halt Further Psychiatric Trials, Redirecting Resources Toward Immunology, Obesity And Epilepsy Programs In 2026
19 décembre·
Yahoo
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know

Communiqués de presse relatifs à l'action Biohaven

Biohaven publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

5 août•
Biohaven
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
28 juillet•
Biohaven
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
23 mai•
Biohaven
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
23 mai•
Biohaven
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
10 mai•
Biohaven
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Biohaven Pharmaceutical Holding Company Ltd. (NYSE - BHVN), Tiga Acquisition Corp. (NYSE - TINV), Lakeshore Acquisition I Corp. (Nasdaq - LAAA), Silicon Motion Te...
10 mai•
Biohaven
BHVN Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Biohaven Pharmaceutical to Pfizer
10 mai•
Biohaven
Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments
9 mai•
Biohaven
Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022
14 avril•
Biohaven
Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability
7 avril•
Biohaven
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
22 février•
Biohaven
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
12 février•
Biohaven
Hardware LDN Debuts Fall/Winter 2022 Collection
3 février•
Biohaven
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
10 janvier•
Biohaven
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
6 janvier•
Biohaven
BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY
15 novembre•
Biohaven
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
27 octobre•
Biohaven
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
27 septembre•
Biohaven
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
27 mai•
Biohaven
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment
23 février•
Biohaven
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
22 février•
Biohaven
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
8 février•
Biohaven
Biohaven Provides Update On ESG Practices
25 janvier•
Biohaven
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
18 janvier•
Biohaven
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
18 janvier•
Biohaven
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
7 janvier•
Biohaven
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
5 janvier•
Biohaven
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
4 janvier•
Biohaven
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
16 décembre•
Biohaven
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
2 décembre•
Biohaven
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series

Biohaven News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Biohaven (BHVN, ISIN : VGG1110E1079). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Biohaven.

Biohaven Action

Biohaven Biohaven Pharmaceutical Holding Co. Ltd. génère ses revenus grâce à la recherche et au développement de candidats-médicaments en phase avancée ciblant les maladies neurologiques et les troubles rares. La société utilise sa plateforme glutamate pour faire avancer des composés en phase clinique pour diverses indications, notamment le trigriluzole dans le cadre des troubles obsessionnels compulsifs, de l'ataxie spinocérébelleuse et de la maladie d'Alzheimer. Par ailleurs, l'entreprise développe le BHV-0223 pour la sclérose latérale amyotrophique (SLA) et le BHV-5000 pour des affections telles que le syndrome de Rett, la douleur neuropathique et la dépression résistante au traitement. Le modèle d'affaires repose sur l'identification et le développement de composés en phase clinique ciblant les indications orphelines neurologiques et d'autres voies neurologiques, la société employant actuellement 825 salariés à plein temps à New Haven, dans le Connecticut.